Navigation Links
Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
Date:5/19/2011

SAN FRANCISCO and SEATTLE, May 19, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.  The preliminary data from the study HEP007 indicated that the risk of death for patients who received JX-594 at the high therapeutic dose was markedly reduced by more than 50 percent (hazard ratio < 0.5) when compared to patients randomized to a control low dose (one-tenth of the high dose). Clinical investigators enrolled approximately 30 patients at sites in the United States, Canada and South Korea.

The data were presented by David Kirn, M.D., president and chief executive officer of Jennerex, today in an oral presentation in the Presidential Symposium of the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Seattle, Washington.  These data were also chosen for inclusion in ASGCT's Media Event to be held during the annual meeting.  Jennerex and its partners expect to present further follow-up on the complete trial data set at a medical conference later this year.

A randomized, placebo-controlled Phase 2b clinical trial of JX-594 in patients with hepatocellular carcinoma (HCC) having failed sorafenib-(Nexavar®) treatment is planned for initiation in the second half of this year; this trial (TRAVERSE), conducted globally with Jennerex's partners, will evaluate survival in advanced HCC patients who have either progressed or exhibited intolerance after treatment with sorafenib, the current standard of care.

"We are extremely encouraged by the promising overall survival results presented today. These results are consistent with a clinically meaningful survival benefit in patients wit
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... April 30, 2015   Tamir Biotechnology , a ... update on its Ebola antiviral therapy program. ... TMR004, is currently being evaluated and considered by a ... against Ebola. During the first quarter of 2015, the ... To Accelerate The Evaluation of Potential Treatments and Vaccines ...
(Date:4/30/2015)... 2015 Nitto Avecia, a leading ... increased capacity and production capability to serve biotechnology ... and service fulfillment continues to drive Nitto Avecia ... throughput capacities. , In Fall 2014, ... process equipment at its Milford, MA facility, which ...
(Date:4/30/2015)... Cambridge, MA & Budapest, Hungary (PRWEB) April 30, ... the only web-based electronic lab notebook with integrated ... leader in providing chemistry software solutions and consulting ... that led to the development of Labguru’s newest ... a set of deep domain features for biologists, ...
(Date:4/30/2015)... , April 30, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that it ... Thursday, May 7, 2015 after the close of the ... call and webcast on Thursday, May 7, 2015 at ... the results and recent corporate developments. For ...
Breaking Biology Technology:Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3
... (Nasdaq: BMRN ) today announced that Jean-Jacques,Bienaime, Chief ... the 3rd Annual Citi Biotech Day in New York ... Interested parties may access a live audio webcast ... BioMarin website, http://www.BMRN.com .,A replay of the call ...
... ANGELES, Sept. 2 Signalife, Inc. (Amex:,SGN) announced ... tomorrow, at,the opening of the market, regarding the ... About Signalife, Signalife, Inc. is a life ... of disease through continuous biomedical signal,monitoring. Signalife uses ...
... Genome,Sciences, Inc. (Nasdaq: HGSI ) announced today ... Annual Healthcare Conference will be webcast,and may be ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ), A member of Human ... overview on Thursday, September 4, 2008 at 8:35 ...
Cached Biology Technology:BioMarin to Present at the Citi Biotech Day 2Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow 2
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... starting March 30 th . The ... New York markets. Gino ... our new ad campaign following the recent initial shipment of ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... $20,000 grant from Orvis Company, Inc. that will help fund ... "Path of the Pronghorn." For more than a ... of pronghorn along the path between wintering grounds in the ... National Park (GTNP). This led to collaboration with GTNP and ...
... (TUM) under Prof. Peter Schieberle and at the University of ... and oils: Lard, butterfat, rapeseed oil and olive oil. Over ... grams of low-fat yoghurt enriched with one of the four ... their normal diet. "Olive oil had the biggest satiety ...
... and the Carlos III University of Madrid have patented a ... a specific street carries each day, by measuring solely the ... world, is an alternative, or a complement, to other methods ... or magnetic discharge levels. This method, designed by the ...
Cached Biology News:More good news for pronghorn 2Olive oil makes you feel full 2A new method for measuring the flow of traffic a street has to bear by measuring atmospheric noise 2
GOAT ANTI HUMAN PSA (ISOFORM 1)...
p-Raf-1 (Ser 338/Tyr 341)-R...
... Lauryl Ether 30% concentration ... Preservative. Surfactant. Clear Solution. ... is 1 mL of ... added to 400 mL ...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
Biology Products: